ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway

Molecular and Cellular Biochemistry

Volumn 359, Issue 1-2, 2012, Pages 235-243

  Lin, Ping ^a   Sun, Xicai ^a   Feng, Tian ^a   Zou, Haifeng ^a   Jiang, Ying ^a   Liu, Zijun ^a   Zhao, Dandan ^a   Yu, Xiaoguang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

ADAM17; AKT; Cell cycle; Cell proliferation; EGFR; Prostate cancer

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PROSTATE CANCER; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

ADAM PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 83555174918     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-1018-8     Document Type: Article

References (42)

1. JW Moul 2003 Population screening for prostate cancer and emerging concepts for young men Clin Prostate Cancer 2 87 97 15040869 (Pubitemid 37296102)
2. AV D'Amico 2003 Therapeutic strategies for localized and locally advanced prostate cancer: combining androgen suppression with definitive local therapy Rev Urol 5 S40 S46 16985976
3. MK Brawer ED Crawford F Labrie A Mendoza-Valdes PD Miller DP Petrylak 2001 Androgen deprivation and other treatments for advanced prostate cancer Rev Urol 3 S59 S68 16986000
4. JJ Peschon JL Slack P Reddy KL Stocking SW Sunnarborg DC Lee WE Russell BJ Castner RS Johnson JN Fitzner RW Boyce N Nelson CJ Kozlosky MF Wolfson CT Rauch DP Cerretti RJ Paxton CJ March RA Black 1998 An essential role for ectodomain shedding in mammalian development Science 282 1281 1284 9812885 10.1126/science.282.5392.1281 1:CAS:528:DyaK1cXnsFejsrw%3D (Pubitemid 28524483)
5. A Merlos-Sua Ârez S Ruiz-Paz J Baselga J Arribas 2001 Metalloprotease-dependent proTGF-a ectodomain shedding in the absence of TACE J Biol Chem 276 48510 48517
6. SW Sunnarborg CL Hinkle M Stevenson WE Russell CS Raska JJ Peschon BJ Castner MJ Gerhart RJ Paxton RA Black DC Lee 2002 Tumor necrosis factor-a converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability J Biol Chem 277 12838 12845 11823465 10.1074/jbc.M112050200 1:CAS:528:DC%2BD38XivFWnsLY%3D (Pubitemid 34952648)
7. CP Blobel 2005 ADAMs: key components in EGFR signalling and development Nat Rev Mol Cell Biol 6 32 43 15688065 10.1038/nrm1548 1:CAS:528:DC%2BD2MXlvVWn (Pubitemid 40064897)
8. S Hart OM Fischer A Ullrich 2004 Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor Cancer Res 64 1943 1950 15026328 10.1158/0008-5472.CAN-03-3720 1:CAS:528:DC%2BD2cXitFCgtL4%3D (Pubitemid 38339438)
9. T Kodama E Ikeda A Okada T Ohtsuka M Shimoda T Shiomi K Yoshida M Nakada E Ohuchi Y Okada 2004 ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor Am J Pathol 165 1743 1753 15509542 10.1016/S0002-9440(10)63429-3 1:CAS:528:DC%2BD2cXhtVCgsb3K (Pubitemid 39435171)
10. F Blanchot-Jossic A Jarry D Masson K Bach-Ngohou J Paineau MG Denis CL Laboisse JF Mosnier 2005 Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells J Pathol 207 156 163 16041691 10.1002/path.1814 1:CAS:528:DC%2BD2MXhtFKnsr7J (Pubitemid 41404146)
11. J Ringel R Jesnowski N Moniaux J Luttges A Choudhury SK Batra G Kloppel M Lohr 2006 Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma Cancer Res 66 9045 9053 16982746 10.1158/0008-5472.CAN-05-3287 1:CAS:528:DC%2BD28Xps1aitbY%3D (Pubitemid 44521123)
12. PA Kenny MJ Bissell 2007 Targeting TACE-dependent EGFR ligand shedding in breast cancer J Clin Invest 117 337 345 17218988 10.1172/JCI29518 1:CAS:528:DC%2BD2sXhs1Oqsbg%3D (Pubitemid 46203962)
13. JE Ruhe S Streit S Hart A Ullrich 2006 EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing Cell Signal 18 1515 1527 16478662 10.1016/j.cellsig.2005.12.003 1:CAS:528: DC%2BD28Xls1aqtLo%3D (Pubitemid 43832087)
14. DC Lee SW Sunnarborg CL Hinkle TJ Myers MY Stevenson WE Russell BJ Castner MJ Gerhart RJ Paxton RA Black A Chang LF Jackson 2003 TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase Ann N Y Acad Sci 995 22 38 12814936 10.1111/j.1749-6632.2003.tb03207.x 1:CAS:528:DC%2BD3sXlsVegu7c%3D (Pubitemid 36706611)
15. PA Kenny 2007 Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer Expert Opin Ther Targets 11 1287 1298 17907959 10.1517/14728222.11.10.1287 1:CAS:528:DC%2BD2sXhtFSgsbvJ (Pubitemid 47604069)
16. M Borrell-Pages F Rojo J Albanell J Baselga J Arribas 2003 TACE is required for the activation of the EGFR by TGF-alpha in tumors EMBO 22 1114 1124 10.1093/emboj/cdg111 1:CAS:528:DC%2BD3sXit1yls74%3D (Pubitemid 36313595)
17. M Ebi H Kataoka T Shimura E Kubota Y Hirata T Mizushima T Mizoshita M Tanaka M Mabuchi H Tsukamoto S Tanida T Kamiya S Higashiyama T Joh 2010 TGFbeta induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells Biochem Biophys Res Commun 402 449 454 20934403 10.1016/j.bbrc.2010.09.130 1:CAS:528:DC%2BC3cXhsVGntrzO
18. AM DeHaan NM Wolters ET Keller KM Ignatoski 2009 EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling Prostate 69 528 537 19143022 10.1002/pros.20903 1:CAS:528: DC%2BD1MXkvVWltbY%3D
19. XH Liu HS Wiley AW Miekle 1993 Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-α and epidermal growth factor/TGF-α receptor J Clin Endocrinol Metab 77 1472 1478 8263129 10.1210/jc.77.6.1472 1:CAS:528: DyaK2cXitlygtQ%3D%3D (Pubitemid 24000898)
20. E Glynne Jones L Goddard ME Harper 1996 Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue Hum Pathol 27 688 694 8698313 10.1016/S0046-8177(96)90399-8 1:STN:280:DyaK28zitVKgtg%3D%3D (Pubitemid 26240321)
21. HY Zhau SM Chang BQ Chen 1996 Androgen-repressed phenotype in prostate cancer Proc Natl Acad Sci USA 93 15152 15157 8986779 10.1073/pnas.93.26.15152 1:CAS:528:DyaK2sXmvF2j (Pubitemid 27009568)
22. C Segrelles M Moral MF Lara S Ruiz M Santos H Leis R Garcia-Escudero AB Martinez-Cruz J Martinez-Palacio P Hernandez C Ballestin JM Paramio 2006 Molecular determinants of Akt-induced keratinocyte transformation Oncogene 25 1174 1185 16247457 10.1038/sj.onc.1209155 1:CAS:528:DC%2BD28Xhs1KisLk%3D
23. X Zheng F Jiang M Katakowski ZG Zhang QE Lu M Chopp 2009 ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation Cancer Biol Ther 8 1045 1054 19395875 10.1158/1535-7163.MCT-09-0369 1:CAS:528:DC%2BD1MXhtVehsbbM
24. YY He SE Council L Feng CF Chignell 2008 UVA-induced cell cycle progression is mediated by a disintegrin and metalloprotease/epidermal growth factor receptor/AKT/Cyclin D1 pathways in keratinocytes Cancer Res 68 3752 3758 18483258 10.1158/0008-5472.CAN-07-6138 1:CAS:528:DC%2BD1cXlvVOitbo%3D
25. M Katakowski F Jiang X Zheng JA Gutierrez A Szalad M Chopp 2009 Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17 Cancer Sci 100 1597 1604 19515085 10.1111/j.1349-7006.2009.01221.x 1:CAS:528:DC%2BD1MXhtFOhurvK
26. M Malumbres M Barbacid 2009 Cell cycle, CDKs and cancer: a changing paradigm Nat Rev Cancer 9 153 166 19238148 10.1038/nrc2602 1:CAS:528: DC%2BD1MXit1ans78%3D
27. J Horiguchi-Yamada H Yamada S Nakada K Ochi T Nemoto 1994 Changes of G1 cyclins, cdk2, and cyclin A during the differentiation of HL60 cells induced by TPA Mol Cell Biochem 132 31 37 8078506 10.1007/BF00925672 1:CAS:528: DyaK2cXltlSqsrw%3D (Pubitemid 24226648)
28. G He J Kuang Z Huang J Koomen R Kobayashi AR Khokhar ZH Siddik 2006 Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21 Br J Cancer 95 1514 1524 17088910 10.1038/sj.bjc.6603448 1:CAS:528:DC%2BD28Xht1CntrzF (Pubitemid 44863354)
29. K Dev CL Frank B Michael R Jöerg M Nicolas L Ming-Fong KB Surinder 2003 Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas Int J Oncol 23 1365 1371
30. HX Wang HM Wang HY Lin Q Yang H Zhang BK Tsang C Zhu 2006 Proteasome subunit LMP2 is required for matrix metalloproteinase-2 and -9 expression and activities in human invasive extravillous trophoblast cell line J Cell Physiol 206 616 623 16222703 10.1002/jcp.20508 1:CAS:528:DC%2BD28XhsFWhtLY%3D (Pubitemid 43191036)
31. GI Shapiro 2006 Cyclin-dependent kinase pathways as targets for cancer treatment J Clin Oncol 24 1770 1783 16603719 10.1200/JCO.2005.03.7689 1:CAS:528:DC%2BD28XksVKgtbg%3D (Pubitemid 46628473)
32. YM Lee P Sicinski 2006 Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human Cell Cycle 5 2110 2114 16969111 10.4161/cc.5.18.3218 1:CAS:528:DC%2BD28XhtlGqsrzI (Pubitemid 44553745)
33. AJ Obaya JM Sedivy 2002 Regulation of cyclin-Cdk activity in mammalian cells Cell Mol Life Sci 59 126 142 11846025 10.1007/s00018-002-8410-1 1:CAS:528:DC%2BD38XhtVSnsbs%3D (Pubitemid 34117361)
34. DO Morgan 1997 Cyclin-dependent kinases: engines, clocks, and microprocessors Annu Rev Cell Dev Biol 13 261 291 9442875 10.1146/annurev. cellbio.13.1.261 1:CAS:528:DyaK1cXisFSktA%3D%3D (Pubitemid 28034527)
35. K Cai BD Dynlacht 1998 Activity and nature of p21(WAF1) complexes during the cell cycle Proc Natl Acad Sci USA 95 12254 12259 9770473 10.1073/pnas.95.21.12254 1:CAS:528:DyaK1cXmsl2rsLk%3D (Pubitemid 28483752)
36. VV Ogryzko P Wong BH Howard 1997 WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases Mol Cell Biol 17 4877 4882 9234744 1:CAS:528:DyaK2sXkvVCntr0%3D (Pubitemid 27318163)
37. R Egilmez S Elagoz EA Kanik 2001 Cdk1/P34Cdc2 and P21waf expression in colorectal adenomas and carcinomas J Exp Clin Cancer Res 20 549 552 11876550 1:CAS:528:DC%2BD38XhtlehtLw%3D (Pubitemid 34087488)
38. JP Stein DA Ginsberg GD Grossfeld SJ Chatterjee D Esrig MG Dickinson S Groshen CR Taylor PA Jones DG Skinner RJ Cote 1998 Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer J Natl Cancer Inst 90 1072 1079 9672255 10.1093/jnci/90.14.1072 1:CAS:528:DyaK1cXkvVOksL4%3D (Pubitemid 28350272)
39. A Gschwind S Hart OM Fischer A Ullrich 2003 TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells EMBO 22 2411 2421 10.1093/emboj/cdg231 1:CAS:528:DC%2BD3sXjvV2gsLo%3D (Pubitemid 36604980)
40. R Seger EG Krebs 1995 The MAPK signaling cascade FASEB J 9 726 735 7601337 1:CAS:528:DyaK2MXmvFCltb0%3D
41. D Bokemeyer A Sorokin MJ Dunn 1996 Multiple intracellular MAP kinase signaling cascades Kidney Int 49 1187 1198 8731081 10.1038/ki.1996.172 1:CAS:528:DyaK28XkslagsL0%3D (Pubitemid 26166398)
42. J Arribas JJ Bech-Serra B Santiago-Josefat 2006 ADAMs, cell migration and cancer Cancer Metastasis Rev 25 57 68 16680572 10.1007/s10555-006-7889-6 (Pubitemid 43723982)